[go: up one dir, main page]

MX2021013947A - Tratamiento profilactico de la infeccion por virus sincitial respiratorio con una vacuna basada en adenovirus. - Google Patents

Tratamiento profilactico de la infeccion por virus sincitial respiratorio con una vacuna basada en adenovirus.

Info

Publication number
MX2021013947A
MX2021013947A MX2021013947A MX2021013947A MX2021013947A MX 2021013947 A MX2021013947 A MX 2021013947A MX 2021013947 A MX2021013947 A MX 2021013947A MX 2021013947 A MX2021013947 A MX 2021013947A MX 2021013947 A MX2021013947 A MX 2021013947A
Authority
MX
Mexico
Prior art keywords
respiratory syncytial
syncytial virus
virus infection
prophylactic treatment
based vaccine
Prior art date
Application number
MX2021013947A
Other languages
English (en)
Inventor
Benoit Christophe Stephan Callendret
Jerald C Sadoff
Paepe Els De
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of MX2021013947A publication Critical patent/MX2021013947A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen métodos para inducir una respuesta inmune protectora contra el virus sincitial respiratorio (VSR) y métodos para prevenir la infección y/o la replicación del VSR, sin inducir un acontecimiento adverso grave en sujetos humanos; los métodos incluyen administrar a los sujetos una cantidad eficaz de un vector adenoviral que codifica un polipéptido F del VSR recombinante que se estabiliza en una conformación de prefusión.
MX2021013947A 2019-05-15 2020-05-14 Tratamiento profilactico de la infeccion por virus sincitial respiratorio con una vacuna basada en adenovirus. MX2021013947A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962848186P 2019-05-15 2019-05-15
PCT/EP2020/063408 WO2020229579A1 (en) 2019-05-15 2020-05-14 Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine

Publications (1)

Publication Number Publication Date
MX2021013947A true MX2021013947A (es) 2021-12-14

Family

ID=70738552

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013947A MX2021013947A (es) 2019-05-15 2020-05-14 Tratamiento profilactico de la infeccion por virus sincitial respiratorio con una vacuna basada en adenovirus.

Country Status (10)

Country Link
US (1) US20220193219A1 (es)
EP (1) EP3969045A1 (es)
JP (1) JP2022532742A (es)
KR (1) KR20220008816A (es)
CN (1) CN113950333A (es)
AU (1) AU2020275910A1 (es)
CA (1) CA3140234A1 (es)
EA (1) EA202193119A1 (es)
MX (1) MX2021013947A (es)
WO (1) WO2020229579A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3319633B1 (en) 2015-07-07 2020-11-11 Janssen Vaccines & Prevention B.V. Vaccine against rsv
DK3439672T3 (da) 2016-04-05 2021-02-15 Janssen Vaccines & Prevention Bv Stabiliserede opløselige præfusions-rsv-f-proteiner
SG11201807912SA (en) 2016-04-05 2018-10-30 Janssen Vaccines & Prevention Bv Vaccine against rsv
EP3464331B1 (en) 2016-05-30 2020-10-28 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
WO2022175479A1 (en) * 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
WO2024193380A1 (zh) * 2023-03-17 2024-09-26 成都威斯克生物医药有限公司 抗呼吸道合胞病毒感染的疫苗

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
JP3816518B2 (ja) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド 相補的なアデノウイルスベクター系と細胞系
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
ATE445705T1 (de) 1995-06-15 2009-10-15 Crucell Holland Bv Verpackungssysteme für humane rekombinante adenoviren zur gentherapie
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5891690A (en) 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
JP2000509614A (ja) 1997-03-04 2000-08-02 バクスター インターナショナル インコーポレイテッド アデノウイルスｅ１−相補性細胞系
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
NZ515582A (en) 1999-05-17 2003-11-28 Crucell Holland B Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
EP1497440B1 (en) 2002-04-25 2008-08-20 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
JP4495587B2 (ja) 2002-04-25 2010-07-07 クルセル ホランド ベー ヴェー 組換えアデノウイルスベクターおよびその使用
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
JP5762408B2 (ja) 2009-08-13 2015-08-12 クルセル ホランド ベー ヴェー ヒト呼吸器合胞体ウイルス（ｒｓｖ）に対する抗体および使用方法
AU2011274472B2 (en) 2010-07-09 2017-03-30 Janssen Vaccines & Prevention B.V. Anti-human respiratory syncytial virus (RSV) antibodies and methods of use
WO2013139911A1 (en) * 2012-03-22 2013-09-26 Crucell Holland B.V. Vaccine against rsv
CA2910067C (en) 2013-04-25 2023-10-17 Crucell Holland B.V. Stabilized soluble pre-fusion rsv f polypeptides
EA034653B1 (ru) 2013-06-17 2020-03-03 Янссен Вэксинс Энд Превеншн Б.В. Стабилизированные растворимые f-полипептиды rsv перед слиянием
SG11201807912SA (en) * 2016-04-05 2018-10-30 Janssen Vaccines & Prevention Bv Vaccine against rsv
US11229692B2 (en) * 2017-05-17 2022-01-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
US11229695B2 (en) * 2017-09-15 2022-01-25 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV

Also Published As

Publication number Publication date
US20220193219A1 (en) 2022-06-23
KR20220008816A (ko) 2022-01-21
EA202193119A1 (ru) 2022-02-18
EP3969045A1 (en) 2022-03-23
AU2020275910A1 (en) 2021-11-04
CA3140234A1 (en) 2020-11-19
CN113950333A (zh) 2022-01-18
WO2020229579A1 (en) 2020-11-19
JP2022532742A (ja) 2022-07-19

Similar Documents

Publication Publication Date Title
MX2021013947A (es) Tratamiento profilactico de la infeccion por virus sincitial respiratorio con una vacuna basada en adenovirus.
MX2023000024A (es) Combinación vacunal contra la infección por el virus respiratorio sincicial.
SA521430813B1 (ar) لقاح وحدات فرعية لعلاج عدوى الجهاز التنفسي أو الوقاية منها
EA202090738A1 (ru) Способ безопасного индуцирования иммунитета против rsv
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
MY166534A (en) Recombinant subunit dengue virus vaccine
EP4272750A3 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
JP2016539946A5 (es)
BR112015002131A8 (pt) Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante
EA201892735A1 (ru) Состав вакцины против hiv
MX363667B (es) Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas.
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
MX2018003352A (es) Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer.
JP2019505560A5 (es)
EP2552490A4 (en) INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF
EA201890042A1 (ru) Вакцина против вируса ящура (вя) на основе рекомбинантного модифицированного вируса осповакцины анкара (mva)
PH12022552084A1 (en) Vaccine against african swine fever virus infection
BR112021022087A2 (pt) Coadministração de vacina sazonal contra influenza e vacina contra vírus respiratório sincicial à base de adenovírus
US20170021009A1 (en) Heat Inactivated Poxvirus Improves Vaccination Results
BR112023021654A2 (pt) Vacina contra vírus
MX2021002449A (es) Vacunas peptidicas.
DK200300015A (da) Anvendelse af stammer af Parapoxvirus ovis til fremstilling af antivirale lægemidler og lægemidler mod cancer
MX2022004060A (es) El uso del agente para inducir inmunidad especifica contra virus de sindrome respiratorio agudo severo sars-cov-2 en sujetos mayores de 60 a?os y/o que tienen enfermedades cronicas (variantes).
NO20055512L (no) Terapi eller prevensjon av respiratoriske, virale infeksjoner med alfa-tyimosinpeptider
WO2021097021A3 (en) Treatment and protection against aspergillus infection and aspergillosis disease